Atrium Therapeutics(RNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RNA Atrium Therapeutics

Market Closed 07-10 16:00:00 EDT

12.46

-0.45

-3.49%

盘后12.46

+0.000.00%

17:41 EDT

High12.87	Low12.20	Vol319.92K
Open12.87	D1 Closing12.91	Amplitude5.19%
Mkt Cap213.14M	Tradable Cap204.02M	Total Shares17.11M
T/O3.98M	T/O Rate1.95%	Tradable Shares16.37M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RNA","market":"US","secType":"STK","nameCN":"Atrium Therapeutics","latestPrice":12.46,"timestamp":1783713600000,"preClose":12.91,"halted":0,"volume":319920,"hourTrading":{"tag":"盘后","latestPrice":12.46,"preClose":12.46,"latestTime":"17:41 EDT","volume":122469,"amount":1525963.74,"timestamp":1783719705624,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03485670023237795,"floatShares":16374250,"shares":17105600,"eps":-3.430739,"marketStatus":"Market Closed","change":-0.45,"latestTime":"07-10 16:00:00 EDT","open":12.87,"high":12.87,"low":12.2,"amount":3977951.18352,"amplitude":0.051898,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.430739,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783929600000},"marketStatusCode":7,"adr":0,"listingDate":1591934400000,"exchange":"NASDAQ","adjPreClose":12.91,"preHourTrading":{"tag":"盘前","latestPrice":12.81,"preClose":12.91,"latestTime":"08:00 EDT","volume":8,"amount":103.69,"timestamp":1783684847633,"change":-0.1,"changeRate":-0.007746,"amplitude":0.030209},"postHourTrading":{"tag":"盘后","latestPrice":12.46,"preClose":12.46,"latestTime":"17:41 EDT","volume":122469,"amount":1525963.74,"timestamp":1783719705624,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.449430321725002,"impliedVol":0.1535,"impliedVolPercentile":0.1572},"requestUrl":"/m/hq/s/RNA/tweets","defaultTab":"tweets","newsList":[{"id":"1167730335","title":"Shanghai's Rural Spring Tourism Season Drives 260 Million Yuan in Consumption, Aiming for Sustainable Popularity","url":"https://stock-news.laohu8.com/highlight/detail?id=1167730335","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167730335?lang=en_us&edition=fundamental","pubTime":"2026-07-08 12:23","pubTimestamp":1783484611,"startTime":"0","endTime":"0","summary":"The Shanghai municipal government recently held a press conference as part of its series on launching the \"15th Five-Year Plan\" period. Officials introduced the \"Shanghai Comprehensive Rural...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA","BK4505","IE0009354923.USD","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649618146","title":"Wave Life Sciences (WVE) Is Up 7.4% After Advancing RNA-Based Obesity Drug Into Phase 2a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2649618146","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649618146?lang=en_us&edition=fundamental","pubTime":"2026-07-05 16:27","pubTimestamp":1783240044,"startTime":"0","endTime":"0","summary":"Wave Life Sciences previously began the Phase 2a multidose portion of its INLIGHT trial for WVE-007 in obesity, building on Phase 1 data that showed a single 240 mg dose reduced waist circumference, visceral fat, and total fat over six months.\nAn important angle for investors is that WVE-007, a GalNAc-siRNA monotherapy, aims to tackle obesity and related conditions through an RNA-based mechanism distinct from GLP-1 drugs.\nWe’ll now examine how advancing WVE-007 into Phase 2a, with earlier...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/wave-life-sciences-wve-is-up-74-after-advancing-rna-based-ob","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/wave-life-sciences-wve-is-up-74-after-advancing-rna-based-ob","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","RNA","BK4585","WVE","BK4007","BK4139","IE0009354923.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646539011","title":"Does Wave Life Sciences’ (WVE) RNA Obesity Program Signal a Shift in Its Competitive Positioning?","url":"https://stock-news.laohu8.com/highlight/detail?id=2646539011","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646539011?lang=en_us&edition=fundamental","pubTime":"2026-06-27 23:19","pubTimestamp":1782573550,"startTime":"0","endTime":"0","summary":"Wave Life Sciences recently initiated the Phase 2a multidose portion of its INLIGHT trial, testing investigational RNA therapy WVE-007 as a monotherapy for individuals with obesity, higher BMI, and cardiometabolic conditions such as type 2 diabetes.\nThe move follows earlier Phase 1 results showing fat loss with muscle preservation and sets up additional Phase 2 studies in 2026 combining WVE-007 with incretins and as a post-incretin maintenance approach, potentially positioning the program...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/does-wave-life-sciences-wve-rna-obesity-program-signal-a-shi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/does-wave-life-sciences-wve-rna-obesity-program-signal-a-shi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BK4585","BK4505","WVE","RNA","BK4588","IE0009354923.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646714368","title":"ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2646714368","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646714368?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:25","pubTimestamp":1782383100,"startTime":"0","endTime":"0","summary":"Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated up","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317367/33039/en/ProQR-Announces-Positive-Phase-1-Target-Engagement-Data-for-AX-0810-Establishing-First-Clinical-Validation-of-the-Axiomer-RNA-Editing-Platform.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4523","IE00BN0W2T93.GBP","BK4187","BK4588","LU1861220207.SGD","CTA","LU2092937221.SGD","BK4121","BK4195","LU0162691827.USD","LU0347712357.USD","LU1429558221.USD","LU2229751404.USD","LU1861217088.USD","BK4505","LU2413666426.HKD","LU0702159343.USD","LU2041044095.USD","LU2089279066.USD","BK4139","BK4211","LU2360107671.USD","LU1435385759.SGD","BA","LU1543694498.USD","IE00BN0W2W23.USD","LU2326559502.SGD","BK4567","BOED","LU0702159699.USD","LU2413666699.HKD","AX","A","G","IE000M9KFDE8.USD","BK4106","BOEG","LU1165135440.EUR","RNA","BK4516","LU0072461881.USD","LU1166156734.SGD","BK4564","IE0009354923.USD","BK4551","BOEU","IE00BN0W2V16.EUR","LU1721428933.USD","BK4226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645698948","title":"Does Labcorp’s New RNA At‑Home ColoSense Screening Win Shift The Bull Case For LH?","url":"https://stock-news.laohu8.com/highlight/detail?id=2645698948","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645698948?lang=en_us&edition=fundamental","pubTime":"2026-06-24 09:27","pubTimestamp":1782264440,"startTime":"0","endTime":"0","summary":"Labcorp has announced the nationwide availability of ColoSense, the only FDA‑approved RNA-based at-home colorectal cancer screening test, now covered for eligible Medicare and Medicare Advantage patients under the updated CMS National Coverage Determination.\nThe launch adds an RNA-based, guideline-supported option with high reported sensitivity for early-stage colorectal cancer, broadening Labcorp’s at-home screening portfolio and potentially reducing barriers to preventive care.\nWe’ll now...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/does-labcorps-new-rna-athome-colosense-screening-win-shift-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/does-labcorps-new-rna-athome-colosense-screening-win-shift-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AIPO","BK4505","AGIX","CHAT","LU0048573561.USD","BK4139","LH","HBCP","LU2237438978.USD","BK4196","LU0742534661.SGD","BK4585","LU1059921491.USD","IE0009354923.USD","LU0251131958.USD","BK4195","ARTY","BK4588","RNA","LU0006061336.USD","LU0251142724.SGD","BK4550","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645596458","title":"Atrium Therapeutics grants 8 new hires stock awards including 66,000 options at $12.66","url":"https://stock-news.laohu8.com/highlight/detail?id=2645596458","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645596458?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:05","pubTimestamp":1782245155,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics granted inducement equity awards to eight newly hired non-executive employees on June 20.Package totals 66,000 non-qualified stock options, exercise price USD 12.66, with 25% vesting at year one then monthly over three years.Also issued 33,000 restricted stock units, with 25% vesting at year one then annually over three years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on June 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL37hFfl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA","BK4505","IE0009354923.USD","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645859615","title":"Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645859615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645859615?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:05","pubTimestamp":1782245100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA9S61TJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4588","IE0009354923.USD","BK4585","BK4505","RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645027931","title":"Circio boosts share capital as it advances circular RNA therapy platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2645027931","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645027931?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:52","pubTimestamp":1782132728,"startTime":"0","endTime":"0","summary":"Targovax ASA ( ($GB:0RIS) ) has issued an announcement. Circio Holding ASA, a biotechnology firm focused on circular RNA expression platforms for n...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/circio-boosts-share-capital-as-it-advances-circular-rna-therapy-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/circio-boosts-share-capital-as-it-advances-circular-rna-therapy-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNA","BK4585","BK4588","BK4505","BK4139","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645049362","title":"Genflow’s Chair to Spotlight Longevity and RNA Therapeutics at BIO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645049362","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645049362?lang=en_us&edition=fundamental","pubTime":"2026-06-22 14:12","pubTimestamp":1782108761,"startTime":"0","endTime":"0","summary":"Genflow Biosciences Plc ( ($GB:GENF) ) has provided an update. Genflow Biosciences said its independent non-executive chairman, Gad Berdugo, will r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genflows-chair-to-spotlight-longevity-and-rna-therapeutics-at-bio-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genflows-chair-to-spotlight-longevity-and-rna-therapeutics-at-bio-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","RNA","LU1169589451.USD","LU1169590202.USD","BIO","BK4505","BK4139","BK4585","BK4588","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644348086","title":"Avidity Biosciences Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2644348086","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644348086?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:00","pubTimestamp":1781787600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 18, 2026 09:00 ET (13:00 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644085617","title":"TransCode Highlights Progress of Lead RNA Cancer Therapeutic","url":"https://stock-news.laohu8.com/highlight/detail?id=2644085617","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644085617?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:39","pubTimestamp":1781786351,"startTime":"0","endTime":"0","summary":"An update from TransCode Therapeutics ( ($RNAZ) ) is now available. On June 18, 2026, TransCode Therapeutics posted an investor presentation outlin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/transcode-highlights-progress-of-lead-rna-cancer-therapeutic?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/transcode-highlights-progress-of-lead-rna-cancer-therapeutic?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","PRGS","DBB","IE0009354923.USD","RNA","BK4585","LU2065732104.USD","BK4588","BK4539","BK4097","RNAZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644702606","title":"Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2644702606","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644702606?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:12","pubTimestamp":1781777543,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald initiated coverage of Atrium Therapeutics (RNA) with an Overweight rating and $25 price target Published first on TheFly – the ul...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atrium-therapeutics-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atrium-therapeutics-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642135464","title":"Circio raises NOK 620 million in 2026 to accelerate circular RNA gene therapy platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2642135464","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642135464?lang=en_us&edition=fundamental","pubTime":"2026-06-10 06:57","pubTimestamp":1781045846,"startTime":"0","endTime":"0","summary":"Targovax ASA ( ($GB:0RIS) ) has provided an update. Circio Holding ASA has raised NOK 300 million in gross proceeds through the exercise of warrant...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/circio-raises-nok-620-million-in-2026-to-accelerate-circular-rna-gene-therapy-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/circio-raises-nok-620-million-in-2026-to-accelerate-circular-rna-gene-therapy-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4585","BK4547","RNA","BK4588","IE0009354923.USD","BK4139","IE00BMPRXR70.SGD","NOK","BK4020","LNOK","IE00BMPRXN33.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642146577","title":"Sirnaomics Sets EGM to Revamp Equity Incentive Schemes","url":"https://stock-news.laohu8.com/highlight/detail?id=2642146577","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642146577?lang=en_us&edition=fundamental","pubTime":"2026-06-09 17:08","pubTimestamp":1780996132,"startTime":"0","endTime":"0","summary":"The latest update is out from Sirnaomics Ltd. ( ($HK:2257) ). Sirnaomics Ltd., a Hong Kong-listed biotechnology company specializing in RNA-based t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sirnaomics-sets-egm-to-revamp-equity-incentive-schemes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sirnaomics-sets-egm-to-revamp-equity-incentive-schemes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","IE0009354923.USD","BK4585","EQR","BK4215","BK4505","RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642452322","title":"Thalia Therapeutics Showcases RNA Strategy in European Biotech Feature","url":"https://stock-news.laohu8.com/highlight/detail?id=2642452322","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642452322?lang=en_us&edition=fundamental","pubTime":"2026-06-09 14:12","pubTimestamp":1780985565,"startTime":"0","endTime":"0","summary":"An announcement from N4 Pharma ( ($GB:THAT) ) is now available. Thalia Therapeutics has highlighted its participation in European Biotechnology Mag...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/thalia-therapeutics-showcases-rna-strategy-in-european-biotech-feature?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/thalia-therapeutics-showcases-rna-strategy-in-european-biotech-feature?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPV","BK4505","XBI","EBAC","RNA","BK4585","BK4588","IE0009354923.USD","BK4139","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640904149","title":"EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2640904149","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640904149?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:41","pubTimestamp":1780486860,"startTime":"0","endTime":"0","summary":"TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, showing safety and disease stabilization in patients with advanced cancer.","market":"sh","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=240,dpr=2,format=auto,quality=85/files/images/story/2026/06/03/Cancer---Heart-Shape-To-Represent-Medica.jpeg","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=240,dpr=2,format=auto,quality=85/files/images/story/2026/06/03/Cancer---Heart-Shape-To-Represent-Medica.jpeg"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/06/52965529/exclusive-transcodes-rna-therapeutic-achieves-64-stable-disease-rate-in-colorectal-cancer-phase-1-study","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/06/52965529/exclusive-transcodes-rna-therapeutic-achieves-64-stable-disease-rate-in-colorectal-cancer-phase-1-study","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","BK4588","RNA","BK4505","BK4585","RNAZ","BK4539","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640153299","title":"Thalia Therapeutics Showcases Differentiated RNA Strategy and Cardiovascular Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2640153299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640153299?lang=en_us&edition=fundamental","pubTime":"2026-06-02 16:05","pubTimestamp":1780387559,"startTime":"0","endTime":"0","summary":"N4 Pharma ( ($GB:THAT) ) has shared an announcement. Thalia Therapeutics has released a video interview with CEO Dr David Solomon, in which he outl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/thalia-therapeutics-showcases-differentiated-rna-strategy-and-cardiovascular-candidate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/thalia-therapeutics-showcases-differentiated-rna-strategy-and-cardiovascular-candidate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3581.USD","IE0002270589.USD","LU1868837136.USD","LU2750360641.GBP","LU1868837300.USD","LU0096364046.USD","LU0106831901.USD","LU0345770993.USD","LU0742534661.SGD","LU1868836914.USD","LU2265009873.SGD","LU1894683264.USD","LU1668664300.SGD","LU0868494708.USD","LU0868494617.USD","IE0034235188.USD","LU2750360997.AUD","LU2471134879.HKD","CSII","IE0009354923.USD","BK4082","LU2237443978.SGD","LU0345770308.USD","LU1791807156.HKD","LU2237443465.HKD","LU2237438978.USD","GSX","BK4505","BK4504","LU1804176565.USD","LU2471134523.USD","BK4550","IE00B19Z3B42.SGD","LU2237443622.USD","LU0061475181.USD","LU1868836591.USD","BK4552","IE0004091025.USD","LU0251131958.USD","LU0942090050.USD","RNA","IE00BFXG1179.USD","LU2471134796.USD","BK4516","LU0251142724.SGD","LU2237443382.USD","LU1894683348.USD","LU0048573561.USD","IE0004086264.USD","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640512819","title":"Wave Life Sciences to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2640512819","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640512819?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:30","pubTimestamp":1780317000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., June  01, 2026  (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304350/0/en/Wave-Life-Sciences-to-Present-at-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","RNA","IE0009354923.USD","BK4505","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640953876","title":"PegBio’s CR059 Wins EASD 2026 Oral Slot, Boosting Circular RNA Metabolic Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2640953876","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640953876?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:17","pubTimestamp":1780309045,"startTime":"0","endTime":"0","summary":"The latest update is out from PegBio Co., Ltd. Class H ( ($HK:2565) ). PegBio announced that its circular RNA-encoded GLP-1 analogue candidate CR05...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pegbios-cr059-wins-easd-2026-oral-slot-boosting-circular-rna-metabolic-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pegbios-cr059-wins-easd-2026-oral-slot-boosting-circular-rna-metabolic-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","RNA","BK4588","BK4585","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640935909","title":"ValiRx fast-tracks RNA helicase deal with McGill and plans Canadian spin-out","url":"https://stock-news.laohu8.com/highlight/detail?id=2640935909","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640935909?lang=en_us&edition=fundamental","pubTime":"2026-06-01 14:12","pubTimestamp":1780294366,"startTime":"0","endTime":"0","summary":"ValiRx plc ( ($GB:VAL) ) just unveiled an update. ValiRx has exercised its option over a second-generation, orally available RNA helicase inhibitor...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/valirx-fast-tracks-rna-helicase-deal-with-mcgill-and-plans-canadian-spin-out?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/valirx-fast-tracks-rna-helicase-deal-with-mcgill-and-plans-canadian-spin-out?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","BK4505","BK4139","BK4588","BK4585","RNA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atriumtherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0872},{"period":"1month","weight":0.0677},{"period":"3month","weight":-0.0197},{"period":"6month","weight":-0.3078},{"period":"1year","weight":-0.3078},{"period":"ytd","weight":-0.3078}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.025613},{"month":2,"riseRate":0.666667,"avgChangeRate":0.084173},{"month":3,"riseRate":0.4,"avgChangeRate":-0.00029},{"month":4,"riseRate":0.4,"avgChangeRate":-0.058331},{"month":5,"riseRate":0.4,"avgChangeRate":-0.018927},{"month":6,"riseRate":0.8,"avgChangeRate":0.113151},{"month":7,"riseRate":0.5,"avgChangeRate":0.027674},{"month":8,"riseRate":0.666667,"avgChangeRate":0.073003},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.048121},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.000506},{"month":11,"riseRate":0.666667,"avgChangeRate":0.096576},{"month":12,"riseRate":0.666667,"avgChangeRate":0.110632}],"exchange":"NASDAQ","name":"Atrium Therapeutics","nameEN":"Atrium Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atrium Therapeutics(RNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Atrium Therapeutics(RNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Atrium Therapeutics,RNA,Atrium Therapeutics股票,Atrium Therapeutics股票老虎,Atrium Therapeutics股票老虎国际,Atrium Therapeutics行情,Atrium Therapeutics股票行情,Atrium Therapeutics股价,Atrium Therapeutics股市,Atrium Therapeutics股票价格,Atrium Therapeutics股票交易,Atrium Therapeutics股票购买,Atrium Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atrium Therapeutics(RNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Atrium Therapeutics(RNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction